Proteus Digital Health Prevails in Trademark Infringement Case
REDWOOD CITY, Calif., (August 1, 2014) -– Proteus® Digital Health, a leading digital medicines company, today announced that it has entered into an agreement settling its claims against Texas-based Proteus Biomedical LLC for trademark infringement and unfair competition. In 2012, Proteus® Digital Health underwent a company rebrand that transitioned the company from Proteus® Biomedical Inc. to Proteus® Digital Health Inc. in order to better reflect the company’s commitment to the emerging digital health industry. The defendant in the lawsuit, Proteus Biomedical LLC, is not, nor has it ever been, in any way related to Proteus® Biomedical Inc. or Proteus® Digital Health Inc.
Manager, Corporate Communications
Proteus Digital Health, Inc.
Tel: +1 650.637.6221
About Proteus® Digital Health™
Proteus Digital Health™ is pioneering a new category of products, services and data systems based on integrating medicines with ingestible, wearable, mobile and cloud computing. Its core technology – the digital health feedback system – provides an unprecedented view into an individual’s personal health choices and physiologic response, allowing patients to better manage their health and more effectively collaborate with caregivers and clinicians, while enabling new information-based business models. Proteus has received a CE mark in Europe and FDA market clearance in the U.S. for its wearable and Ingestible Sensor™ devices. Headquartered in Redwood City, Calif., Proteus is privately held and funded by Carlyle, Essex Woodlands, Kaiser Permanente®, Medtronic®, Novartis®, Otsuka®, Oracle®, ON Semiconductor® and other investors. Further information is available at: www.proteus.com